Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis

Rheumatology

Volumn 45, Issue 1, 2006, Pages 43-49

  Nakamura, T ^a   Higashi, S ^a   Tomoda, K ^a   Tsukano, M ^a   Baba, S ^b   Shono, M ^c  

^a Kumamoto Center for Arthritis and Rheumatology   (Japan)

^b Fukuroi Municipal Hospital   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amyloidosis; Rheumatoid arthritis; SAA1.3 allele

Indexed keywords

ACTARIT; ALBUMIN; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; BUCILLAMINE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; LEFLUNOMIDE; LOBENZARIT; METHOTREXATE; MIZORIBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; SALAZOSULFAPYRIDINE; SERUM AMYLOID A;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ALLELE; AMYLOIDOSIS; ARTICLE; BIOPSY TECHNIQUE; CAUSE OF DEATH; CLINICAL FEATURE; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GASTROINTESTINAL DISEASE; GENOTYPE; HEART AMYLOIDOSIS; HOMOZYGOSITY; HUMAN; INFECTION; JAPAN; KIDNEY AMYLOIDOSIS; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK FACTOR; SURVIVAL; SYMPTOMATOLOGY; UNIVARIATE ANALYSIS;

AMYLOIDOSIS; ARTHRITIS, RHEUMATOID; CAUSE OF DEATH; FEMALE; GENOTYPE; HOMOZYGOTE; HUMANS; JAPAN; MALE; MIDDLE AGED; PROGNOSIS; SERUM AMYLOID A PROTEIN; SURVIVAL ANALYSIS;

EID: 29844441293     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei112     Document Type: Article

References (52)

1. Cunnane G. Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 2001;13:67-73.
2. Migita K, Abiru S, Nakamura M et al. Lipopolysaccharide signaling induces serum amyloid A (SAA) synthesis in human hepatocytes in vitro. FEBS Lett 2004;569:235-9.
3. Migita K, Miyashita T, Maeda Y et al. An active metabolite of leflunomide, A771726, inhibits the production of serum amyloid A protein in human hepatocytes. Rheumatology 2005;44:443-8.
4. Cunnane G, Whitehead AS. Amyloid precursors and amyloidosis in rheumatoid arthritis. Bailliere's Clin Rheumatol 1999;13:615-28.
5. Wakhlu A, Krisnani N, Hissaria P, Aggarwal A, Misra R. Prevalence of secondary amyloidosis in an Asian north Indian patients with rheumatoid arthritis. J Rheumatol 2003;30:948-51.
6. Baba S, Masago SA, Takahashi T et al. A novel allelic variant of serum amyloid A, SAA1γ: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 1995;4:1083-7.
7. Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Baba S. Massive hematuria due to bladder amyloidosis in patients with rheumatoid arthritis: Three case reports. Clin Exp Rheumatol 2003;21:673-4.
8. Nakamura T, Yamamura Y, Tomoda K, Tsukano M, Shono M, Baba S. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003;22:371-5.
9. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
10. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
11. Lansbury J. The pooled index. J Rheumatol 1977;4:445-6.
12. Nakamura T, Baba S, Yamamura Y et al. Combined treatment with cyclophosphamide and prednisolone is effective for secondary amyloidosis with SAA1 γ/γ genotype in a patient with rheumatoid arthritis. Mod Rheumatol 2000;10:160-4.
13. Aristarco GS, Claudio LPC, Abdul JT, James BS, Thomas TS, Emilio RG. M-mode and two-dimensional echocardiographic features in cardiac amyloidosis. Circulation 1981;63:188-96.
14. Garcia R, Saeed SM. Amyloidosis. Cardiovascular manifestations in five illustrative cases. Arch Intern Med 1968;121:259-66.
15. Tanaka F, Migita K, Honda S et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 2003;21:343-6.
16. Sizuki A, Ohosone Y, Obana M et al. Cause of death in 81 autopsied patients with rheumatoid arthritis. J Rheumatol 1994;21:33-6.
17. Gertz MA, Kyle RA. Secondary systemic amyloidosis: Response and survival in 64 patients. Medicine 1991;70:246-56.
18. Joss N, McLaughlin K. Simpson K, Boulton-Jones JAM. Presentation, survival and prognostic markers in AA amyloidosis. Q J Med 2000;93:535-42.
19. Gratacos J, Orellana C, Sanmarti R et al. Secondary amyloidosis in ankylosing spondylitis: A systematic survey of 137 patients using abdominal fat aspiration. J Rheumatol 1997;24:912-5.
20. Gomez-Casanovas E, Sanmarti R, Sole M, Canate JD, Munoz-Gomez J. The clinical significance of amyloid fat deposits in rheumatoid arthritis. A systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum 2001;44:66-72.
21. Mansoury TME, Hazenberg BPC, Badawy SAE et al. Screening for amyloid in subcutaneous fat tissue of Egyptian patients with rheumatoid arthritis: clinical and laboratory characteristics. Ann Rheum Dis 2002;61:42-7.
22. Kobayashi H, Tada S, Fuchigami T et al. Secondary amyloidosis in patients with rheumatoid arthritis: Diagnostic and prognostic value of gastroduodenal biopsy. Br J Rheumatol 1996;35:44-9.
23. Carmona L, Gonzalez-Alvaro I, Balsa A, Belmonte MA, Tena X, Sanmarti R. Rheumatoid arthritis in Spain: Occurrence of extra-articular manifestations and estimates of disease severity. Ann Rheum Dis 2003;62:897-900.
24. Gonzalez-Alvaro I, Carmona L, Balsa A et al. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. J Rheumatol 2003;30:697-704.
25. Misra R, Wakhlu A, Krishnani N, Hissaria P, Aggarwal A. Prevalence of silent amyloidosis in rheumatoid arthritis and its clinical significance. J Rheumatol 2004;31:1013-4.
26. 1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid 1998;5:262-5.
27. Moriguchi M, Terai C, Koseki Y et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet 1999;105:360-6.
28. Yamada T, Okuda Y, Takasugi K et al. An allele of serum amyloid A1 associated with amyloidosis in both Japanese and Caucasians. Amyloid 2003;10:7-11.
29. Nakamura T, Tomoda K, Tsukano M, Yamamura Y, Baba S. Gustatory sweating due to autonomic neuropathy in a patient with amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol 2004;14:498-501.
30. Faulkes DJ, Betts JC, Woo P. Characterization of five human serum amyloid A1 alleles. Amyloid 1994;1:255-62.
31. Liepnieks JJ, Kluve-Beckerman B, Benson MD. Characterization of amyloid A protein in human secondary amyloidosis: The predominant deposition of serum amyloid A1. Biochim Biophys Acta 1995; 1270:81-6.
32. Yamada T, Okuda Y, Takasugi K, Itoh K, Igari J. Relative serum amyloid A (SAA) values: The influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:124-7.
33. Gillmore JO, Levitt LB, Jersey MA, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.
34. Maini RN, Breedveld FC, Kalden JR et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
35. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21(Suppl. 31):154-64.
36. Moriguchi M, Terai C, Kaneko H et al. A novel single-nucleotide polymorphism at the 5′-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum 2001; 44:1266-72.
37. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
38. Voskuyl AE, Zwinderman AH, Weestedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996;39:266-71.
39. Tuglular S, Yalcinkaya F, Paydas S et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-5.
40. Odabas AR, Cetinkaya R, Selcuk Y, Erman Z, Bilen H. Clinical and biochemical outcome of renal amyloidosis. Int J Clin Pract 2002;56:342-4.
41. McGill NW, Tuck R, Hassall JE. Severe autonomic neuropathy in amyloidosis secondary to rheumatoid arthritis. Aust NZ J Med 1986;16:705-7.
42. Arima T, Ando Y, Ando E et al. Secondary amyloidosis with severe autonomic dysfunctions. J Auton Nerv Sys 1995;52:77-81.
43. Edmonds ME, Jones TC, Saunders WA, Sturrock RD. Autonomic neuropathy in rheumatoid arthritis. Br Med J 1979;2:173-5.
44. David J, Vouyiouka O, Ansell BM, Hall A, Woo P. Amyloidosis in juvenile chronic arthritis: A morbidity and mortality study. Clin Exp Rheumatol 1993;2:85-90.
45. Keysser G, Keysser C, Keysser M. Treatment of refractory rheumatoid arthritis with low-dose cyclophosphamide. Long-term follow-up of 108 patients. Z Rheumatol 1998;57:101-7.
46. Berglund K, Keller C, Thysell H. Alkylating cytostatic treatment in renal amyloidosis secondary to rheumatoid arthritis. Ann Rheum Dis 1987;46:757-62.
47. Ahlmen M, Ahlmen J, Svalander C, Bucht H. Cytotoxic drug treatment of reactive amyloidosis in rheumatoid arthritis with special reference to renal insufficiency. Clin Rheumatol 1987;6:27-38.
48. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in the management of renal AA-amyloidosis: A 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993;20:2051-7.
49. Chevrel G, Jenvrin C, McGregor B, Miossec P. Renal type AA amyloidosis associated with rheumatoid arthritis: A cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology 2001;40:821-5.
50. Gottenberg J-E, Merle-Vincent F, Bentaberry F et al. Anti-tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides. A followup report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-24.
51. Smith GR, Tymms KE, Falk M. Eternercept treatment of renal amyloidosis complicating rheumatoid arthritis. Intern Med J 2004; 34:570-2.
52. Maezawa A, Hiromura K, Mitsuhashi H et al. Combined treatment with cyclophosphamide and prednisolone can induce remission of nephritic syndrome in a patient with renal amyloidosis, associated with rheumatoid arthritis. Clin Nephrol 1994;42:30-2.